Last updated 5 days ago

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

360 patients around the world
Available in United States, Brazil, Spain, Argentina
Merck Sharp & Dohme LLC
4Research sites
360Patients around the world
This study is for people with
Lymphoma
Hodgkin lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Alemán
Recruiting
Av. Pueyrredón 1640, CABA, Buenos Aires
Centro Oncológico de Integración Regional C.O.I.R.
Recruiting
Monte Caseros 1020, Mendoza
Hospital de Câncer de Barretos - Fundação PIO XII
Recruiting
Rua Antenor Duarte Villela 1331 - Barretos, Sao Paulo, 14784-400
Hospital Paulistano
Recruiting
Sao Paulo, 01321-001
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy